undefined undefined undefined

The impact of a chronic obstructive pulmonary disease diagnosis on the identification of heart failure

Event: ESC Congress 2025

Topic: Comorbidities

Session: Heart failure and multi-organ impact: treatment approaches

Access

Like

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

Access

Like

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Angiotensin and angiotensin receptor neprilysin inhibitors in heart failure

Access

Like

The efficiency of dapagliflozin as add-on therapy in obese patients with resistant hypertension and chronic kidney disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Hypertension e-posters

Access

Like

Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin

Event: ESC Congress 2021 - The Digital Experience

Topic: Obesity

Session: Risk Factors and Prevention ePosters

Access

Like

The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Event: ESC Congress 2021 - The Digital Experience

Topic: Pharmacotherapy

Session: Chronic heart failure e-posters

Access

Like

The efficacy and safety of mineralocorticoid-receptor antagonists: spironolactone and eplerenone in resistant hypertension and chronic kidney disease stages 3

Event: ESC Congress 2019

Topic: Pharmacotherapy

Session: Hypertension treatment: drugs and devices

Access

Like

The relationship between plasma renin and aldosterone levels and the reduction of blood pressure with spironolactone in patients with resistant hypertension.

Event: ESC Congress 2019

Topic: Renin-Angiotensin System

Session: Secondary hypertension and genes

Access

Like

The renin and aldosterone levels at resistant hypertension and its connection with other clinical features

Event: ESC Congress 2018

Topic: Renin-Angiotensin System

Session: Hyperaldosteronism and hypertension: look harder!

Access

Like

undefined undefined undefined

Contributor content

The impact of a chronic obstructive pulmonary disease diagnosis on the identification of heart failure

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

Safety and efficacy of initiation SGLT in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease on top of standard therapy with ARNI or ACE-i

The efficiency of dapagliflozin as add-on therapy in obese patients with resistant hypertension and chronic kidney disease

Weight loss therapy in obese hypertensive patients: the effect of orlistat versus metformin

The risks and benefits of spironolactone use in heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

The efficacy and safety of mineralocorticoid-receptor antagonists: spironolactone and eplerenone in resistant hypertension and chronic kidney disease stages 3

The relationship between plasma renin and aldosterone levels and the reduction of blood pressure with spironolactone in patients with resistant hypertension.

The renin and aldosterone levels at resistant hypertension and its connection with other clinical features

ESC 365 is supported by